vimarsana.com
Home
Live Updates
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictiba
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictiba
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacksZUG, Switzerland, Feb. 22, 2024 -- Pharvaris , a...
Related Keywords
Russia ,
Israel ,
United Kingdom ,
Canada ,
Switzerland ,
Washington ,
United States ,
Ukraine ,
American ,
Joan Mendivil ,
Marca Riedl ,
Peng Lu ,
Wave Ii Disease Specific Program ,
Exchange Commission ,
European Union ,
American Academy Of Allergy ,
Waltere Washington Convention Center ,
American Academy ,
Scientific Meeting ,
Clinical Immunology ,
Oral Deucrictibant ,
Hereditary Angioedema Attacks ,
Chief Medical Officer ,
Treat All ,
Patient Satisfaction ,
On Demand Treatment ,
Specific Program ,
Statement Regarding Forward Looking ,
Annual Report ,
Markets ,